Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas).
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; Vienna Consensus Conference participants. Pape UF, et al. Among authors: reed n. Neuroendocrinology. 2016;103(2):144-52. doi: 10.1159/000443165. Epub 2016 Jan 5. Neuroendocrinology. 2016. PMID: 26730583 Free article. No abstract available.
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.
Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). Borbath I, et al. J Neuroendocrinol. 2022 Mar;34(3):e13105. doi: 10.1111/jne.13105. Epub 2022 Mar 1. J Neuroendocrinol. 2022. PMID: 35233848 Review.
Unmet Needs in Appendiceal Neuroendocrine Neoplasms.
Toumpanakis C, Fazio N, Tiensuu Janson E, Hörsch D, Pascher A, Reed N, O Apos Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape UF, Grozinsky-Glasberg S, Scoazec JY; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Toumpanakis C, et al. Among authors: reed n. Neuroendocrinology. 2019;108(1):37-44. doi: 10.1159/000493894. Epub 2018 Sep 20. Neuroendocrinology. 2019. PMID: 30235454 Review.
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. Niederle B, et al. Among authors: reed n. Neuroendocrinology. 2016;103(2):125-38. doi: 10.1159/000443170. Epub 2016 Jan 12. Neuroendocrinology. 2016. PMID: 26758972 Free article. No abstract available.
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.
Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants. Partelli S, et al. Among authors: reed n. Neuroendocrinology. 2017;105(3):255-265. doi: 10.1159/000464292. Epub 2017 Feb 25. Neuroendocrinology. 2017. PMID: 28237989 No abstract available.
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants. Falconi M, et al. Among authors: reed n. Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5. Neuroendocrinology. 2016. PMID: 26742109 Free PMC article. No abstract available.
ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.
Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. Knigge U, et al. Among authors: reed n. Neuroendocrinology. 2017;105(3):310-319. doi: 10.1159/000458155. Epub 2017 Feb 17. Neuroendocrinology. 2017. PMID: 28222443 Free article. No abstract available.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: reed n. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Strosberg J, et al. Among authors: reed n. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123969 Free PMC article. Clinical Trial.
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B. Ruszniewski P, et al. Among authors: reed n. Neuroendocrinology. 2004;80(4):244-51. doi: 10.1159/000082875. Epub 2004 Dec 22. Neuroendocrinology. 2004. PMID: 15627802 Clinical Trial.
750 results